id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-350232-zml4o93t	Peck, Richard W	A Real‐World Evidence Framework for Optimising Dosing in All Patients with COVID‐19	2020-05-23		.txt	text/plain	1931	89	43	Several drugs are being repurposed into clinical trials in COVID-19 patients, ranging from drugs already well established in other diseases, such as chloroquine/hydroxychloroquine, lopinavir+ ritonavir, azithromycin and tocilizumab/sarilumab, to those such as remdesivir still in development for their initial indication (1) . This will help maximise the value from all the data being collected in the many trials now ongoing, will be more informative than many separate models each developed from smaller datasets and will allow faster achievement of a consensus for how to adjust dosing of effective drugs to optimise responses in all patients. This should also now include working together to ensure optimal use of effective treatments in all real-world patients. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modelling approach for effective drug repurposing A model-and real world data-based framework for continuous updating of dosing recommendations and labelling of treatments for COVID-19 patients (hsCRP: high sensitivity C-reactive protein, Rx: treatment, PKPD: pharmacokinetic/pharmacodynamics, VK: viral kinetic.	./cache/cord-350232-zml4o93t.txt	./txt/cord-350232-zml4o93t.txt